Printer Friendly

First Reliance Bancshares declares preferred stock and trust preferred securities dividends.

M2 EQUITYBITES-June 17, 2015-First Reliance Bancshares declares preferred stock and trust preferred securities dividends

(C)2015 M2 COMMUNICATIONS http://www.m2.com

First Reliance Bancshares Inc (OTC:FSRL) revealed on Tuesday the return to cash dividend payments on its preferred stock originally issued to the US Treasury as part of the Troubled Asset Relief Program (TARP) and now held by private investors, besides, interest on its outstanding trust preferred securities.

Further, the company stated that it had stopped these payments since November 2011.

Payments on the deferred dividends on the TARP preferred stock totalled USD4.2m and were made in May 2015. The deferred interest payments on outstanding trust preferred securities totalled USD876,657 and the company said that interest payable on the trust preferred securities had continued to accrue and as a result the payment of the deferred amount had no effect on current earnings and capital.

The company's wholly owned subsidiary bank's leverage ratio, Tier 1 risk-based capital ratio and total risk-based capital ratio were 11.64%, 14.22% and 15.14%, respectively, exceeding all regulatory requirements.

First Reliance was founded in 1999 and is based in Florence, South Carolina. It is the parent company of First Reliance Bank that provides various consumer and business banking services to individuals, small and medium-sized businesses.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 17, 2015
Words:226
Previous Article:Medivir reorganises R&D structure and optimises resources through a partnership with GVK BIO.
Next Article:Pulmatrix partners with Mylan for ex-US development of PUR0200 for the treatment of COPD.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters